Overall, our results suggest that PIDDosome activation and consequent inhibition of the NF-κB/miR-21/PDCD4 pathway by DCA occurs both in vitro and in vivo, providing new mechanistic insights into its role as a putative pathogenic factor for hepatic disorders. Here, NFKB1 is linked to liver disorder.